The day in pharma, read in minutes.
NewsAnalytik Jena Opens €96M German Facilities to Expand Lab Capacity
Analytik Jena opens €96M German facilities, expanding lab instrumentation output that could ease procurement pressure for pharma QC labs.
FDA Creates CDER Exclusivity Board to Standardize Drug Rulings
Alcon Wins FDA Approval for Brytly Nonprescription Eye Drops
FDA Warns of Bacterial Contamination in Counterfeit Eye Drops
EMA CHMP Recommends Six Medicines for Approval in October 2026
Latest news
11 storiesAdial Appoints David Rubenstein as Chief Scientist for AT177
Adial Pharmaceuticals names tapinarof architect David Rubenstein as Chief Scientist to lead AT177 through IND-enabling studies toward 2027 first-in-human trials.
Dermata Reports Positive Results from Tome Skincare Study
Dermata Therapeutics reports topline cosmetic study data for Tome Foundational Treatment, with 71% of participants showing improvement after one application.
Oryzon Secures Vafidemstat Patent Allowances in Four Markets
Oryzon secures vafidemstat patent grants in South Korea, Philippines, New Zealand, and Mexico ahead of a Phase III BPD trial.
Zealand Pharma Partners With Generate on $1.2B AI Obesity Deal
Zealand Pharma and Generate Biomedicines partner to use generative AI for novel obesity protein therapeutics, raising early manufacturing and regulatory questions.
Rasonque Gains CHMP Positive Opinion for Pancreatic Cancer
CHMP recommends Rasonque for metastatic pancreatic cancer after a phased review completed in under 150 days, setting a regulatory precedent.
Lonza Completes Its CDMO Transformation After CHI Divestment
Lonza completes its CDMO transformation after divesting Capsules & Health Ingredients, reshaping capacity and pricing for biologics and small molecule clients.
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer
Evotec appoints Dr. Joanna Holbrook as CSO effective November 2026, bringing AI, omics, and translational medicine expertise to its discovery platform.
Enodia Therapeutics Signs Pfizer Deal Worth Over $500 Million
Enodia Therapeutics and Pfizer sign a $500M deal; Pfizer takes full manufacturing and regulatory control post-collaboration.
Insmed Advances Four Phase 3 TPIP Studies
Insmed's PALM program runs four parallel Phase 3 TPIP studies across pulmonary diseases, targeting 2,000+ patients with a once-daily dry powder inhaler.
Par Health Recalls 22 Lots of Argatroban Injection
Par Health recalls 22 Argatroban Injection lots over multi-material particulate contamination, including stopper fragments and possible stainless steel.
FDA Updates Blood Donation Compliance Policy
FDA CBER finalizes compliance policy on blood donation suitability and Source Plasma quarantine holds under 21 CFR 630.30, 630.10(c)(2), and 640.69(f).
Worth your time this week
FDA Launches Rare Disease Framework Initiative
Hepion Pharmaceuticals Acquires Gravitas Life Sciences
FibroBiologics Secures Australian Patent for Disc Regeneration
